Cargando…

Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals

For refractory chronic hepatitis C, interferon (IFN)-based triple-agent combination therapy with second-generation direct-acting antivirals (DAAs) has been established as the standard treatment method. The rate of decrease in the viral load and the negative conversion of hepatitis C virus (HCV) RNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	ISHIKAWA, TORU, ABE, SATOSHI, WATANABE, TAKAYUKI, NOZAWA, YUJIRO, SANO, TOMOE, IWANAGA, AKITO, SEKI, KEIICHI, HONMA, TERASU, YOSHIDA, TOSHIAKI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888019/ https://www.ncbi.nlm.nih.gov/pubmed/27313853 http://dx.doi.org/10.3892/br.2016.660

Ejemplares similares

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2016)

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment
por: Ishikawa, Toru, et al.
Publicado: (2018)

Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2017)

Comparison of the efficacy of self-expandable metallic stents in colorectal obstructions caused by extracolonic malignancy and colorectal cancer
por: Sano, Tomoe, et al.
Publicado: (2021)

Eosinophilic esophagitis in Japanese patients: A mild and slow-progressing disorder
por: Sato, Hiroki, et al.
Publicado: (2018)

Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve
por: ISHIKAWA, TORU, et al.
Publicado: (2015)

Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy
por: Ishikawa, Toru, et al.
Publicado: (2020)

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
por: Imai, Michitaka, et al.
Publicado: (2020)

Clinical Usefulness of Transjugular Liver Biopsy in Patients With Hematological Diseases With Liver Dysfunction
por: Ishikawa, Toru, et al.
Publicado: (2021)

Cone beam versus conventional computed tomography angiography volume measurement in partial splenic embolization
por: Ishikawa, Toru, et al.
Publicado: (2019)

Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia
por: Ishikawa, Toru, et al.
Publicado: (2019)

Analysis of predictors after partial splenic embolization for thrombocytopenia with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2022)

Predictive Factor of Local Recurrence after Balloon-Occluded TACE with Miriplatin (MPT) in Hepatocellular Carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2014)

Hemorrhagic Gastric Metastasis from Hepatocellular Carcinoma Successfully Treated Using Coil Embolization of the Left Gastric Artery
por: Imai, Michitaka, et al.
Publicado: (2019)

Risk factors for difficult endoscopic hemostasis for colonic diverticular bleeding and efficacy and safety of transcatheter arterial embolization
por: Sano, Tomoe, et al.
Publicado: (2023)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Ascending Colon Varices Due to Left-sided Portal Hypertension
por: Ishikawa, Toru, et al.
Publicado: (2021)

Comparison of Ablation Volume Between Emprint(®) and Mimapro(®) Systems for Hepatocellular Carcinoma –A Preliminary Study
por: Ishikawa, Toru, et al.
Publicado: (2023)

Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
por: Alexopoulou, Alexandra, et al.
Publicado: (2015)

Interferon-Free Regimens and Direct-Acting Antiviral Agents for Delta Hepatitis: Are We There Yet?
por: Nemteanu, Roxana, et al.
Publicado: (2023)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
por: Lima, Viviane D., et al.
Publicado: (2015)

Antiviral activities of interferons
por: Stewart, William E., et al.
Publicado: (1979)

Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
por: Ramamurthy, Narayan, et al.
Publicado: (2018)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal, Sanaa M
Publicado: (2014)

Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma
por: Teng, Wei, et al.
Publicado: (2019)

Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report
por: Kurokawa, Ken, et al.
Publicado: (2020)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
por: Sung, Pil Soo, et al.
Publicado: (2020)

Interferon-inducible antiviral effectors
por: Sadler, Anthony J., et al.
Publicado: (2008)

Antiviral defense: interferons and beyond
por: Stetson, Daniel B., et al.
Publicado: (2006)

Avian Interferons and Their Antiviral Effectors
por: Santhakumar, Diwakar, et al.
Publicado: (2017)

Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelled by phylogenetic analysis
por: Cuypers, Lize, et al.
Publicado: (2018)

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon
por: Mascia, Claudia, et al.
Publicado: (2017)

Development of the Antiviral State in Response to Interferon
por: Sonnabend, Joseph A., et al.
Publicado: (1970)

Direct Antiviral Mechanisms of Interferon-Gamma
por: Kang, Soowon, et al.
Publicado: (2018)

Interferons: Signaling, antiviral and viral evasion
por: Bonjardim, Cláudio A., et al.
Publicado: (2009)

The regulation of antiviral activity of interferon epsilon
por: Zhao, Fu-Rong, et al.
Publicado: (2022)

Viral recognition and the antiviral interferon response
por: Dalskov, Louise, et al.
Publicado: (2023)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nmo04e54cmdajvo4p0klsethsl